Netherlands' clinical trial lag impedes drug access, industry warns

The Netherlands is falling behind in clinical trials, a critical issue that threatens both drug accessibility and the translation of research into treatments, according to a recent industry warning. Hollandbio, the industry association, highlights a growing concern that Europe's capacity and willingness to convert life sciences innovation into tangible healthcare benefits for its citizens is being impeded.

Annemiek Verkamman of Hollandbio stated that the broader biotech debate hinges on whether Europe is "able, allowed and willing to turn research into treatments," a sentiment underscored by the Dutch lag. Effective clinical trials are fundamental to developing and approving new medicines. For instance, the More-EUROPA project aims to enhance the understanding of drug effects by developing standards for real-world data, thereby improving the efficiency of clinical trial programs. Similarly, the PRIME-ROSE consortium is generating clinical evidence through pragmatic clinical trials to increase access to optimised cancer treatments. These initiatives demonstrate a clear European commitment to advancing clinical trial methodologies.

However, the Dutch situation suggests a bottleneck in this research-to-treatment pipeline. The challenge extends beyond the Netherlands; a recent report urged Belgium to unite its biotech sector under a national consortium to address similar scaling problems. This regional fragmentation and slow clinical trial progress collectively raise questions about the speed and effectiveness with which European innovation reaches patients.

What this means: The Netherlands' struggle with clinical trial performance indicates a broader European challenge in optimising the pathway from scientific discovery to patient care. Addressing this requires a concerted effort to streamline processes, increase investment, and ensure regulatory environments support rapid clinical development.